Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.63 |
| ▸ | CD74 | P04233 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5302441 | 0.88 | MIF (0.63) | MIFCD74L3MBTL1KMT2AMEN1 | |
| SCHEMBL16250472 | 0.87 | HPGD (0.64) | MIFCD74L3MBTL1KMT2AMEN1 | |
| SCHEMBL16186527 | 0.83 | L3MBTL1 (0.74) | MIFCD74L3MBTL1KMT2AMEN1 | |
| SCHEMBL29670895 | 0.82 | KMO (0.74) | KMT2AMEN1ALDH1A1KMO | |
| SCHEMBL30660242 | 0.82 | CBX7 (0.62) | KMT2AMEN1NPC1KMO | |
| SCHEMBL5416540 | 0.82 | CBX7 (0.62) | KMT2AMEN1NPC1KMO | |
| SCHEMBL2953606 | 0.82 | KMO (0.74) | KMT2AMEN1ALDH1A1KMO | |
| SCHEMBL2950965 | 0.81 | KMO (0.76) | MIFCD74KMO | |
| SCHEMBL29957877 | 0.81 | KMO (0.76) | MIFCD74KMO | |
| SCHEMBL13367744 | 0.81 | MIF (0.66) | MIFCD74L3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8937087-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-23 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315963-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD1, DRD2, OPRD1 | MIF 4509/4885CD74 4439/4885L3MBTL1 2687/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | MIF 636/4885CD74 475/4885L3MBTL1 2280/4885 |
| US-20150045402-A1 | HETEROCYCLIC ACETAMIDE COMPOUND | DRD2, DRD1, OPRD1 | MIF 4256/4885CD74 4380/4885L3MBTL1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.